title: Guidelines for the Prophylaxis of Pneumocystis jirovecii Pneumonia (PJP) in Children With Solid Tumors.
abstract: Although it is well-established that children undergoing allogeneic stem cell transplants and treatment for leukemia should be offered prophylaxis against Pneumocystis jirovecii pneumonia, the risk for children with solid malignancies is less certain. This guideline has been developed with the aim of standardizing practice and optimizing the benefit versus risk of prophylactic medication in this group of patients. P. jirovecii pneumonia has a high mortality rate even with prompt antimicrobial treatment. Since prophylaxis with co-trimoxazole is safe, effective, and inexpensive, we suggest that all children with malignancies undergoing immunosuppressive therapy are offered prophylaxis unless there are clear contraindications.
authors.affiliation: *Department of Paediatrics, John Radcliffe Hospital, Oxford †Centre for Reviews and Dissemination, University of York, York ‡Paediatric Oncology Department, University Hospitals Nottingham NHS Trust, Queen's Medical Centre, Nottingham, UK.
authors.forename: Rebecca
authors.initials: R
authors.lastname: Proudfoot
authors.forename: Bob
authors.initials: B
authors.lastname: Phillips
authors.forename: Sophie
authors.initials: S
authors.lastname: Wilne
mesh_terms: D019072:Antibiotic Prophylaxis / Q000379:methods*; D002648:Child; D006801:Humans; D009369:Neoplasms / Q000150:complications* / Q000628:therapy; D045363:Pneumocystis carinii; D011020:Pneumonia, Pneumocystis / Q000209:etiology / Q000382:microbiology / Q000517:prevention & control*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use
chemical_list: D015662:Trimethoprim, Sulfamethoxazole Drug Combination